Monopar Therapeutics (MNPR) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for August 5, 2024, with record date of July 12, 2024; stockholders to vote on four key proposals including director elections, auditor ratification, a reverse stock split, and an amendment to the stock incentive plan.

• Board unanimously recommends voting FOR all proposals and director nominees.

• Proxy materials and annual report are available online; voting can be done by internet, mail, or in person.

Voting matters and shareholder proposals

• Proposal 1: Election of six directors to serve until the next annual meeting.

• Proposal 2: Ratification of BPM LLP as independent registered public accounting firm for 2024.

• Proposal 3: Approval of a reverse stock split at a ratio between 1-for-2 and 1-for-20, at Board's discretion, to regain Nasdaq compliance.

• Proposal 4: Amendment to the 2016 Stock Incentive Plan to increase shares available for awards by 2,000,000.

• No other business or director nominees expected at the meeting.

Board of directors and corporate governance

• Six current directors nominated, with diverse backgrounds in biopharma, finance, and business.

• Four directors are independent per Nasdaq standards; no family relationships among directors or executive officers.

• Board committees: Audit, Compensation, Corporate Governance & Nominating, and Plan Administrator, each with defined charters and annual self-evaluations.

• Board diversity matrix provided; one female, one Asian, and four white directors.